🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Biohaven shares rise on positive trial results, analyst maintains buy rating

EditorLina Guerrero
Published 09/23/2024, 02:23 PM
BHVN
-

On Monday, Biohaven Pharmaceutical Holding Company (NYSE:BHVN) received continued support from TD Cowen with a reiterated Buy rating and a steady price target of $55.00. This endorsement follows the announcement of successful clinical trial results for their drug troriluzole, which is being studied for the treatment of Spinocerebellar Ataxia (SCA).

The company had previously faced a setback last summer when a request for the drug's approval was refused. However, a revised study design was agreed upon with the FDA, leading to the recent positive outcome. The new study indicated that troriluzole could slow the progression of SCA by 50-70%. With these findings, Biohaven plans to file for approval by the end of the year.

The analyst from TD Cowen highlighted the significance of the prespecified analysis of the study, suggesting that it appears robust. The optimism is further bolstered by the potential for troriluzole to reach the market by the end of 2025, presenting a multi-billion dollar opportunity for Biohaven.

The success of the trial is a pivotal moment for Biohaven, as it could mark a turnaround from last year's regulatory refusal. The company's commitment to pursuing an effective treatment for SCA could soon materialize into a therapeutic option for patients, pending regulatory approval.

Biohaven's trajectory is closely watched by investors, as the company moves toward potentially introducing troriluzole to the market. The positive trial results and the maintained confidence from TD Cowen suggest a promising future for the pharmaceutical firm.

In other recent news, Biohaven Pharmaceutical Holding has been making significant strides in drug development. The company's drug troriluzole has shown promising results in trials for Spinocerebellar Ataxia (SCA), a neurodegenerative disorder.

This has led to increased optimism from Baird, which has maintained its Outperform rating and raised its price target from $58 to $60. BTIG also maintains a Buy rating, citing consistency with expected progression patterns for different types of SCA.

Piper Sandler has reiterated an Overweight rating on Biohaven shares, with a price target of $76.00, following the unexpected success of troriluzole in SCA clinical trials. The company is expected to file a New Drug Application in the next quarter, with potential commercialization in 2025. The firm Jefferies and Bernstein SocGen Group have initiated coverage on Biohaven with Buy and Outperform ratings respectively, emphasizing the potential of the company's diverse portfolio.


InvestingPro Insights


As Biohaven Pharmaceutical Holding Company (NYSE:BHVN) garners attention following its promising clinical trial results for troriluzole, investors are considering various facets of the company's financial health and market performance. An InvestingPro Tip highlights that Biohaven holds more cash than debt on its balance sheet, which may provide financial flexibility as the company works towards drug approval. Additionally, the fact that two analysts have revised their earnings upwards for the upcoming period could indicate growing confidence in Biohaven's prospects. On the market performance side, Biohaven has seen a high return over the last year, with a 138.57% price total return, signaling strong investor enthusiasm.

Key InvestingPro Data metrics to consider include Biohaven's current market cap of $3.82 billion and a high Price / Book multiple of 9.95, reflective of the market's valuation of the company's assets relative to its share price. Despite these strong points, it's also noted that the company is not currently profitable, with a negative P/E ratio of -4.13. Biohaven's next earnings date is set for November 6, 2024, which will be a pivotal moment for investors tracking the company's progress.

For investors seeking a deeper dive into Biohaven's financials and market potential, there are additional InvestingPro Tips available that provide a more comprehensive analysis of the company's performance and outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.